bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
| Property | Value | Notes |
|---|---|---|
| Primary target | MC4R | Highest reported functional activity |
| Peak plasma time | About 1 hour | Subcutaneous administration |
| Elimination half-life | A few hours | Active fragment may extend effect |
| Main clearance route | Proteolytic degradation | Not cytochrome-dependent |
| Typical assay | LC-MS/MS | Plasma quantification |
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Metabolically label O-GlcNAc to install O-GlcNAz onto proteins Use click chemistry to link IsoTaG probe to O-GlcNAz Use streptavidin beads to enrich for tagged proteins Treat beads with trypsin to release non-modified peptides Cleave isotopically recoded glycopeptides from beads using mild acid Obtain a full-scan mass spectrum from isotopically recoded glycopeptides Apply algorithm to detect unique isotope signature from probe Perform tandem MS on the isotopically recoded species to obtain glycopeptide amino acid sequences Search protein database for identified sequences Other methodologies have been developed for quantitative profiling of O-GlcNAc using differential isotopic labeling. Example probes generally consist of a biotin affinity tag, a cleavable linker (acid- or photo-cleavable), a heavy or light isotopic tag, and an alkyne. O-GlcNAc modification has also been recently reported on tyrosine residues, though these represent roughly 5% of all O-GlcNAc modifications.
=== Economics === Pregabalin is available as a generic medication in a number of countries, including the United States as of July 2019. In the United States as of July 2019 the wholesale/pharmacy cost for generic pregabalin is $0.17–0.22 per 150-mg capsule. From 2008 until 2018, Pfizer engaged in extensive direct-to-consumer advertising campaigns to promote its branded product Lyrica for fibromyalgia and diabetic nerve pain indications. In January 2016, the company spent a record amount, $24.6 million for a single drug on TV ads, reaching global revenues of $14 billion, more than half in the United States. Up until 2009, Pfizer promoted Lyrica for other uses that had not been approved by medical regulators. For Lyrica and three other drugs, Pfizer was fined a record amount of $2.3 billion by the Department of Justice, after pleading guilty to advertising and branding "with the intent to defraud or mislead". Pfizer illegally promoted the drugs, with doctors "invited to consultant meetings, many in resort locations; attendees expenses were paid; they received a fee just for being there", according to prosecutor Michael Loucks.
=== Economics === In June 2020, Gilead announced that it had set the price of remdesivir at US$390 per vial for the governments of developed countries, including the United States, and US$520 for US private health insurance companies. The expected course of treatment is six vials over five days for a total cost of US$2,340. Being a repurposed drug, the minimum production cost for remdesivir is estimated at US$0.93 per day of treatment. In July 2020, the European Union secured a €63 million (US$74 million) contract with Gilead, to make the drug available there in early August 2020. In October 2020, Gilead Sciences and the European Commission announced they had signed a joint procurement framework contract in which Gilead agreed to provide up to 500,000 remdesivir treatment courses over the next six months to 37 European countries. Among the contracting countries were all 27 EU member states plus the United Kingdom, "Albania, Bosnia & Herzegovina, Iceland, Kosovo, Montenegro, North Macedonia, Norway, and Serbia". At the time, the price per treatment course was not disclosed; Reuters reported the price was 2,070 euros, thereby implying the total value of the contract (if all 500,000 courses are ordered) is approximately €1.035 billion. Under the contract, each participating country will directly place orders with Gilead and pay Gilead directly for its own orders.
== Structure of glycolysis components in Fischer projections and polygonal model == The intermediates of glycolysis depicted in Fischer projections show the chemical changing step by step. Such image can be compared to polygonal model representation.
Sources: en.wikipedia.org
== Structure == The carbohydrate moieties of AGPs are rich in arabinose and galactan, but other sugars may also be found such as L-rhamnopyranose (L-Rhap), D-mannopyranose (Manp), D-xylopyranose (Xylp), L-fucose (Fuc), D-glucopyranose (Glcp), D-glucuronic acid (GlcA) and its 4-O-methyl derivative, and D-galacturonic acid (GalA) and its 4-O-methyl derivative. The AG found in AGPs is of type II (type II AGs) – that is, a galactan backbone of (1–3)-linked β-D-galactopyranose (Galp) residues, with branches (between one and three residues long) of (1,6)-linked β-D-Galp. In most cases, the Gal residues terminate with α-L-arabinofuranose (Araf) residues. Some AGPs are rich in uronic acids (GlcA), resulting in a charged polysaccharide moiety, and others have short oligosaccharides of Araf. Specific sets of hydroxyproline O-β-galactosyltransferases, β-1,3-galactosyltransferases, β-1,6-galactosyltransferases, α-arabinosyltransferases, β-glucuronosyltransferases, α-rhamnosyltransferases, and α- fucosyltransferases are responsible for the synthesis of these complex structures. One of the features of type II AGs, particularly the (1,3)-linked β-D-Galp residues, is their ability to bind to the Yariv phenylglycosides. Yariv phenylglycosides are widely used as cytochemical reagents to perturb the molecular functions of AGPs as well as for the detection, quantification, purification, and staining of AGPs. Recently, it was reported that interaction with Yariv was not detected for β-1,6-galacto-oligosaccharides of any length.
An association between hearing loss and high level exposures to PFNA was also reported in 2020. PFOA is classified as carcinogenic to humans (Group 1) by the International Agency for Research on Cancer (IARC), with significant associations with the onset of liver, pancreatic, and uterine cancers. IARC also classified PFOS as possibly carcinogenic to humans (Group 2b) based on "strong" mechanistic evidence. Evidence suggests PFOA, perfluorohexanesulfonic acid (PFHxS), and perfluorononanoic acid (PFNA) cause hepatotoxicity in humans and links PFAS exposure to male infertility.
=== 8 May === The Verkhovna Rada passed a bill allowing for the voluntary mobilization of convicts into the Ukrainian Armed Forces for a chance at parole. Those convicted of violent crimes, treason, rape, terrorism or drug dealing would be barred from volunteering. The bill requires Zelenskyy's signature to become law. Ukrainian Justice Minister Denys Maliuska subsequently said in an interview that between 10,000 and 20,000 convicts could be recruited if the bill is signed into law. One person was killed by Russian shelling in Kherson Oblast. Russia claimed to have taken the villages of Kyslivka in Kharkiv Oblast, 20 kilometers from Kupiansk, and Novokalynove, ten kilometers north of Avdiivka. The Ukrainian military confirmed that Russian forces had entered Krasnohorivka and were holed up in the town's refractory plant. A spokesman for Ukraine's Khortytsia operational-strategic group said that its units, mainly the 59th Brigade, had blocked the Russians inside the refractory plant and claimed to have killed 30 Russians over the past day. The governor of Kharkiv Oblast, Oleh Syniehubov, reported a large gathering of Russian forces north of the region. A jury-rigged Kh-101 modified with a second high explosive warhead containing steel fragments was shot down over Ukraine. The EU agreed to donate €3 billion in income from frozen Russian assets to Ukraine "for arms purchases and reconstruction".
Sources: en.wikipedia.org
== Medical career == Coatsworth is a Fellow of the Royal Australasian College of Physicians. His specialties are respiratory medicine and infectious diseases. He is currently director of infectious diseases at Canberra Hospital. His other roles have included executive director at the National Critical Care and Trauma Response Centre in Darwin. He has also lectured in medicine at the Australian National University. Coatsworth led humanitarian teams in the Congo and the Darfur region of Sudan for Medicins Sans Frontiers when he was 25, a task that he says left him with PTSD. He told the Today programme: "I think everyone has their limits in life and I kind of reached that, the security situation there was really difficult. There was the threat of assassination of people in the place where we were." After returning home, Coatsworth became anxious: "I felt like I was having these heart palpitations ... At the end of 2019 it got to the point one weekend I couldn't leave the house." He took anxiety medication to resolve the issue. He was elected to the board of Medicins Sans Frontiers in Australia in 2008. He served as the board's president in 2010 and 2011. He also led the second Australian Medical Assistance Team to the Philippines after Typhoon Haiyan in 2013. His other deployments with the Australian Medical Assistance Team include Vanuatu after Cyclone Pam in 2015 and Fiji following Cyclone Winston in 2016. In 2023, Coatsworth joined Patients Australia as Ambassador for Health Reform.
=== Polysaccharide chiral stationary phases === The naturally occurring polysaccharide form the basis for an important group of columns designed for chiral separation. The main polysaccharides are cellulose, amylose, chitosan, dextran, xylan, curdlan, and inulin. Polysaccharide-based stationary phase have a high loading capacity, many chiral centers and complicated stereochemistry, and can be used for the separation of a wide range of compounds. Polysaccharide-based chiral stationary phases have a wide application due to their high separation efficiency, selectivity, sensitivity and reproducibility under normal and reversed-phase conditions, as well as their broad applicability for structurally diversified compounds. The mechanism of chiral interaction on the polysaccharide-based chiral stationary phase has not yet been elucidated. However, the following interactions are believed to play a role in the retention: (i) Hydrogen bonding interactions of the polar chiral analyte with carbamate groups on the CSP; (ii) π-π interactions between phenyl groups on the CSP and aromatic groups of the solute; (i) Dipole-dipole interactions (ii) Steric interactions due to the helical structure of the CSP. These effects on the retention process originate also from the functionality of the derivatives of the polysaccharide, its average molecular weight, and size distribution, the solvent used to immobilize it on the macroporous silica support, and the nature of the macroporous silica support itself.
=== Combinatorial extension === The combinatorial extension (CE) method is similar to DALI in that it too breaks each structure in the query set into a series of fragments that it then attempts to reassemble into a complete alignment. A series of pairwise combinations of fragments called aligned fragment pairs, or AFPs, are used to define a similarity matrix through which an optimal path is generated to identify the final alignment. Only AFPs that meet given criteria for local similarity are included in the matrix as a means of reducing the necessary search space and thereby increasing efficiency. A number of similarity metrics are possible; the original definition of the CE method included only structural superpositions and inter-residue distances but has since been expanded to include local environmental properties such as secondary structure, solvent exposure, hydrogen-bonding patterns, and dihedral angles. An alignment path is calculated as the optimal path through the similarity matrix by linearly progressing through the sequences and extending the alignment with the next possible high-scoring AFP pair. The initial AFP pair that nucleates the alignment can occur at any point in the sequence matrix. Extensions then proceed with the next AFP that meets given distance criteria restricting the alignment to low gap sizes. The size of each AFP and the maximum gap size are required input parameters but are usually set to empirically determined values of 8 and 30 respectively.
== Sizes == While small-scale columns range from inner diameters of 0.5 cm and withstand pressures of up to 130 MPa, industrial large scale columns reach diameters of up to 2 m and operate at considerable lower pressures (below 1 MPa). While it is favorable to view the packed bed of a column large scale columns are manufactured from steel due to its superior resilience. Chromatography columns can be used as stand-alone devices or in combination with manual or automated chromatography systems. Medium to large columns are almost exclusively operated together with automated systems to decrease the risk of process failure and loss of product.
Sources: en.wikipedia.org
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.
Elimination is rapid, with a half-life of a few hours. An active fragment circulates after breakdown, so biological activity may outlast measurable parent drug. This is one reason single-timepoint measurements are limited.
Because breakdown is mainly proteolytic rather than cytochrome-dependent, classic metabolic interactions are less likely. Agents affecting blood pressure could still matter. Formal interaction studies are sparse.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.